Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 2:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 7,061 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Refractory or Unexplained Chronic Cough
Interventions: NOC-110, Placebo; Drug · Other
Lead sponsor: Nocion Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 68
States / cities: Foley, Alabama • Scottsdale, Arizona • Tempe, Arizona + 60 more

Conditions: Alcohol Dependence, Bipolar Disorder
Interventions: Acamprosate, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Systemic Lupus Erythematosus
Interventions: LY3361237, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 19
States / cities: Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 16 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT005 MDI, Formoterol Fumarate 12 μg (Foradil® Aerolizer®), Formoterol Fumarate 24 μg (Foradil® Aerolizer®), Placebo MDI; Drug · Other
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 3
States / cities: Clearwater, Florida • Tampa, Florida • Spartanburg, South Carolina

Conditions: Ulcerative Colitis
Interventions: TAK-279, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • Murrieta, California • Clearwater, Florida + 13 more

Conditions: Ulcerative Colitis
Interventions: RO7049665, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Healthy
Interventions: ALXN2050, ALXN2050-matching Placebo, Moxifloxacin, Moxifloxacin-matching Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Schizophrenia, Negative Symptoms
Interventions: Vortioxetine, Placebo; Drug · Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 3
States / cities: Lauderdale Lakes, Florida • Grand Rapids, Michigan • Glen Oaks, New York

Conditions: Overactive Bladder
Interventions: AOBO-001, Placebo; Drug
Lead sponsor: American Oriental Bioengineering, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Mobile, Alabama • West Palm Beach, Florida • Newton, Kansas + 2 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Interferon beta-1a, Ocrelizumab-matching placebo, Ocrelizumab, Interferon beta-1a-matching placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 821 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 40
States / cities: Phoenix, Arizona • Carmichael, California • La Jolla, California + 32 more

Conditions: Acute Leukaemia
Interventions: Daunorubicin, Cytarabine, Eltrombopag, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 14
States / cities: Farmington, Connecticut • Miami, Florida • Orlando, Florida + 11 more

Conditions: Agitation, Dementia
Interventions: BXCL501, Matching Placebo; Drug
Lead sponsor: BioXcel Therapeutics Inc; Industry
Eligibility: 65 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 7
States / cities: Los Alamitos, California • Daytona Beach, Florida • Maitland, Florida + 4 more

Conditions: Smallpox
Interventions: tecovirimat, Placebo; Drug · Other
Lead sponsor: SIGA Technologies; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 449 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 11
States / cities: Mobile, Alabama • Redding, California • San Diego, California + 8 more

Conditions: Autism Spectrum Disorder
Interventions: N acetyl cysteine, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 3 Years to 12 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Methamphetamine Dependence
Interventions: Bupropion, Placebo; Drug · Other
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 12
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 9 more

Conditions: Friedreich's Ataxia
Interventions: varenicline, placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Tampa, Florida • Philadelphia, Pennsylvania

Conditions: Symptomatic Menopause, Cognitive Impairments
Interventions: Lisdexamfetamine, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus, Hypertension, Metabolic Disease, Obesity, Sleep Apnea Syndrome
Interventions: Orlistat, Placebo; Drug
Lead sponsor: Jack Yanovski; NIH
Eligibility: 12 Years to 17 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: GLPG1690, Placebo; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 40 Years and older
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 47
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 42 more

Conditions: Renal Failure, Coronary Artery Disease, Surgery, Surgery-Complications
Interventions: CoQ10 1200 mg orally with Glutathione 1000 mg orally, Group B: Placebo CoQ10 orally and Placebo Glutathione orally; Drug
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Tuberculosis
Interventions: TBA-354, Placebo; Drug · Other
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Cystic Fibrosis
Interventions: ivacaftor, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 6 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Eosinophilic Esophagitis
Interventions: Famotidine, Loratadine, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Atopic Dermatitis
Interventions: OPA-15406, Tacrolimus, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 12
States / cities: Mobile, Alabama • Hot Springs, Arizona • Irvine, California + 9 more

Search by objective public record fields.

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough

Acamprosate vs. Placebo in Bipolar Alcoholics

A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

PT005 MDI Dose Ranging Versus Foradil Aerolizer Study

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)

A Study of the Cardiac Effects of ALXN2050 in Healthy Adults

Adjunctive Vortioxetine in Schizophrenia

Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

A Safety and Efficacy Study of Eltrombopag in Subjects With AML

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat

Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial

Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence

Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia

Attention & Memory Impairments in Menopausal Women

Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases

A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

Prevent Cardiac Surgery Associated AKI Trial

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects

Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients

Antihistamines in Eosinophilic Esophagitis

A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis